Global oncology research has increasingly emphasized the importance of the tumor immune microenvironment (TiME)—the complex interplay between cancer cells and surrounding immune components such as Treg, Teff, and MDSC. These immune dynamics often determine treatment response, disease progression, and long-term outcomes.
Traditionally, obtaining TiME information has relied on tissue biopsy, which is invasive and unsuitable for repeated monitoring.
Cell Envision introduces a blood-based approach by analyzing circulating tumor microemboli (CTM). Through CTM-driven liquid profiling, clinicians can observe critical immune interactions surrounding the tumor without the need for tissue sampling. This technology enables a deeper understanding of:
- Whether the tumor is under immunosuppressive pressure led by Treg
- Early signs of tumor evolution or immune escape
- The authenticity and durability of treatment response
- The need to reassess or adjust therapeutic strategies
These insights are difficult to capture through conventional imaging or standard blood tests. By bringing TiME assessment into a liquid-based format, Cell Envision provides clinicians with a novel tool for dynamic immune monitoring.
Cell Envision will showcase the clinical applications and future development of this technology at the Taiwan Healthcare Expo. We warmly welcome clinicians, researchers, and industry partners to visit us and explore potential collaborations.
Exhibition Venue: Hall 1, Taipei Nangang Exhibition Center (TaiNEX 1)｜Cell Envision Booth: #L621a
Exhibition Dates: Dec 04 – Dec 07